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I
schaemic heart disease (IHD) and stroke are the world's leading causes of death, accounting for a combined 15 million deaths in 2013. 1) Both IHD and strokes are known to be caused by vascular troubles such as vascular occlusion or vascular rupture and, in particular among the elderly, these vascular diseases are accompanied by atherosclerosis. In this regards, much attention has been paid to the elucidation of the mechanisms in which atherosclerosis forms. Atherogenesis is generally initiated by endothelial injury, which is associated with risk factors including diabetes mellitus, smoking, dyslipidemia, and hypertension. This stress-induced endothelial injury subsequently provokes activation of the renin-angiotensin system (RAS), infiltration of inflammatory cells, and oxidative stress, all of which synergistically contribute to the formation of the atherosclerosis. Accordingly, current therapeutic interventions for the prevention of IHD are directed at these risk factors. Indeed, by intervening in these risk factors, especially dyslipidemia and hypertension, the incidence of cardiovascular disease and its mortality were dramatically reduced. In particular, angiotensin converting enzyme inhibitors (ACEi), antihypertensive agents that act via RAS inhibition, have been proven to be powerful agents for reducing atherosclerosis in coronary arteries, thereby reducing the incidence of IHD. 2, 3) This was a plausible result because ACEi act on both the risk factor (hypertension) and its modifier (RAS) of atherosclerosis. However, one calcium channel blocker, amlodipine, once considered to be a mere vasodilator, was reported to reduce cardiovascular death as efficiently as the ACEi enalapril in patients with coronary disease and normal blood pressure (BP). 4) The mechanism by which amlodipine affects IHD beyond BP lowering has long remained unclear.
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In the current issue of International Heart Journal, Kayamori, et al. provided a novel mechanism of the antiatherogenic effects of amlodipine treatment on a murine experimental model of atherosclerosis using apolipoprotein E-deficient (ApoE KO) mouse on high fat diet (HFD).
5) The authors first focused on the components of amlodipine, consisting of two enantiomers, the S-enantiomer and R+ enantiomer. The former has L-type calcium channel blocking activity while the latter has 1,000-fold weaker activity. 6) To determine the anti-atherogenic effects of amlodipine beyond vasodilation, ApoE KO mice on HFD were subjected to either vehicle, amlodipine (Senantiomer plus R+ enantiomer), and R+ enantiomer, both at doses low enough so that no BP reduction was observed. Notwithstanding the unchanged BP or serum total cholesterol levels between the 3 groups, both amlodipine and R+ enantiomer treatments equally exhibited a significant reduction in aortic intimal formation, an early stage of atherosclerosis. Intriguingly, these anti-atherogenic effects of amlodipine and R+ enantiomer were positively correlated with the anti-senescence effects and antiinflammatory effects, which were represented by the reduction of senescence-associated β-galactosidase (SA-β gal) positive cell number and the reduction of proinflammatory cytokine gene expressions, respectively. Since these effects were observed without BP reduction, a hallmark of calcium channel blocker action by the Senantiomer of amlodipine, the authors reasoned these effects derived from R+ enantiomer action. It has been reported that amlodipine releases nitric oxide (NO) independently of calcium blocking activity, and that NO serves as an anti-oxidant agent in blood vessels. 7, 8) Since p 53, a critical inducer of senescence, is known to be induced by oxidative stress, the authors conducted an experiment to determine whether the anti-senescence effects of amlodipine and R+ enantiomer are attributable to the NO production and subsequent inhibition of oxidative stress-induced p53 activation. As expected, the p53 activity was induced by H2O2 treatment in VSMC in vitro and this p53 activation was significantly ameliorated by the treatment with amlodipine and R+ enantiomer, implying the anti-senescence effect of these drugs. These effects were then abolished by an NO synthase inhibitor, L-NAME, suggesting that the anti-senescent effects were attributable to their ability to release NO from VSMC, pos-Harada, ET AL Figure. A proposed mechanism of the anti-atherogenic effects of amlodipine via NO-induced p53 inhibition. AT2R indicates angiotensin-2 receptor; and B2R, kinin B2 receptor.
sibly independent of a BP lowering effect through calcium channel blockade. Given that amlodipine reportedly increases NO release through angiotensin II type 2 receptor (AT2R) -bradykinin -B2-kinin receptor (B2R) axis, the authors speculated that the anti-atherogenic effects of amlodipine via NO release were possibly associated with AT 2R and B2R actions (Figure) .Accumulating evidence suggests that vascular senescence is critically involved in atherosclerosis formation. SA-β gal positive senescent cells were present in VSMC and endothelial cells in vessels of patients with atherosclerosis.
9) The existence of these senescent vascular cells is reported to be both a result and a cause of atherosclerosis. 10) During the plaque formation, VSMC proliferation and a decline of NO lead to telomere shortening and oxidative stress, respectively, causing vascular cell senescence. On the other hand, senescent vascular cells are known to acquire a unique senescence-associated secretory profile (SASP) that includes many proinflammatory cytokines, resulting in the infiltration of inflammatory cells into the vascular walls and the development of atherosclerosis. This relationship between cellular senescence and inflammation is termed "inflammaging" and was well documented in this study, whereby amlodipine and R+ enantiomer successfully attenuated the induction of proinflammatory cytokine, interleukin (IL)-1β gene expression in conjunction with p53 protein expressions, contributing to the prevention of atherosclerosis. 11) Jemerson, et al. reported that a combination of benazepril, an ACEi, plus amlodipine was superior to that of benazepril plus hydrochlorothiazide treatment in the relative risk reduction of cardiovascular events in patients with hypertension.
12) The mechanisms by which amlodipine showed better risk reduction than diuretics when combined with ACEi treatment in the high-risk patients remain unknown, however, Kayamori's study may in part explain this mechanism. 5) A report by Chen, et al. that ACEi ameliorated vascular injury through the bradykinin-NO system further support the notion in this study that NO produced by vascular cells plays a pivotal role in the prevention of atherogenesis through the anti-senescence and anti-inflammatory effects of amlodipine.
13) Nevertheless, further studies are required to elucidate the mechanisms of the amlodipine-mediated vascular protective effects in the atherogenic condition.
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